tion and sustainable growth. Together with our competitive edges developed over the previous years, we are well-positioned to weather the challenges arising from the external policy changes and market competition. More importantly, after the completion of our internal integration during the past 2 years, as well as having experienced various challenges in the past, Sihuan Pharmaceutical has become more mature and stable, with its overall competitive strengths significantly enhanced."
Rebounds of Key CCTV Products and Rapid Growth of Fast-growing Promising Products Boosted Strong Growth in SalesCCV Products
Thanks to a young and diversified product portfolio, sales of CCV products grew 73.4% to RMB2,214.7 million during the review period, which accounted for 95.3% of total revenue, and again making CCV products the Company's largest revenue contributor. The Company achieved significant improvement in sales of Kelinao and Oudimei, its two major exclusive products. As the Company stepped up its support to its distributors for academic promotion and deepened its penetration into third to fourth tier cities, sales of Kelinao increased by 32.1% year-on-year. As for Oudimei, the Company was able to deepen penetration in existing markets and expand into new markets by winning tenders at stable price levels in more provinces, and supplementary tender submissions in provinces where tenders were delayed. As a result, sales of Oudimei jumped 140.1% year-on-year in the first half of 2013.
Moreover, sales of the Company's two other exclusive products, Yuanzhijiu and Yeduojia, maintained rapid sales growth during the period, with sales of the products up 120.8% and 560.9% to RMB202.0 million and RMB129.4 million, respectively. Sales of the Company's other promising products, namely Danshen Chuanxiongqin injection, Guhong injection and Yimaining, also grew significantly by 157.2%, 109.6% and 53.3% to RMB 57.1 million, RMB151.2 million and RMB92.7 million
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Sihuan Pharmaceutical Holdings Group Ltd.|
Copyright©2012 PR Newswire.
All rights reserved
. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies2
. Sihuan Pharmaceutical Announces 2012 Annual Results3
. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride4
. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China5
. Sihuans First-to-market Generic Drug Roxatidine Receives New Drug Certificate and Approval for Production6
. Sihuan Pharmaceutical Announces 2012 Interim Results7
. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration8
. Immune Pharmaceuticals Completes Merger with EpiCept Corporation9
. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash10
. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings11
. Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg